SCI Pharmtech, Inc. (TPE:4119)

Taiwan · Delayed Price · Currency is TWD

45.50

+0.75 (1.68%)

At close: Jul 9, 2026

-28.68% (1Y)

Market Cap	5.44B -32.8%
Revenue (ttm)	1.36B -13.7%
Net Income	95.75M -81.7%
EPS	0.80 -81.6%
Shares Out	119.51M
PE Ratio	56.79
Forward PE	n/a
Dividend	0.75 (1.68%)
Ex-Dividend Date	Jul 1, 2026

Volume	139,433
Open	45.30
Previous Close	44.75
Day's Range	44.75 - 45.60
52-Week Range	39.60 - 63.70
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, an... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1987

Employees 239

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 4119

Full Company Profile

Financial Performance

In 2025, SCI Pharmtech's revenue was 1.34 billion, a decrease of -11.81% compared to the previous year's 1.52 billion. Earnings were 107.37 million, a decrease of -79.92%.

Financial Statements